Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758331 | 0.94 | MEN1 (0.58) | TMEM97SIGMAR1KMT2AMEN1HTT | |
| SCHEMBL25758458 | 0.87 | SLC6A2 (0.61) | PRMT6CARM1KMT2AMEN1HTT | |
| SCHEMBL23648940 | 0.86 | TMEM97 (0.58) | PRMT6CARM1TMEM97SIGMAR1KMT2A | |
| SCHEMBL24069354 | 0.86 | PRMT6 (0.56) | PRMT6CARM1KMT2AMEN1HTT | |
| SCHEMBL25759276 | 0.86 | PRMT6 (0.56) | PRMT6CARM1KMT2AMEN1HTT | |
| SCHEMBL25248038 | 0.84 | HTR7 (0.63) | PRMT6CARM1KMT2ASMN1; SMN2SLC6A2 | |
| SCHEMBL25758335 | 0.84 | HTR7 (0.62) | KMT2AMEN1HTTSMN1; SMN2SLC6A2 | |
| SCHEMBL30376178 | 0.82 | HTR7 (0.69) | PRMT6CARM1TMEM97SIGMAR1KMT2A | |
| SCHEMBL24070204 | 0.82 | HTR7 (0.56) | TMEM97SIGMAR1KMT2AMEN1HTT | |
| SCHEMBL26213100 | 0.82 | KMT2A (0.48) | PRMT6CARM1SIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | claimed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | disclosed |
| EP-4159718-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | PRMT6 2897/4885CARM1 4741/4885TMEM97 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.